You just read:

Janssen Submits Supplemental New Drug Application to U.S. FDA for INVOKANA® (canagliflozin) for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Mar 28, 2019, 08:30 ET